BUYOUT OFFER Right now, I doubt anything under $5
Post# of 8387
(Total Views: 243)
Posted On: 04/19/2025 1:30:16 PM
BUYOUT OFFER
Right now, I doubt anything under $50 million would be considered (accounting for loans, etc.). That's out of my range, but in the future - after the pps increases, loans are paid off and a share buyback is implemented - I could see a point where a group of shareholders could get together and leverage their shareholdings to make an offer. Years ago, Simpsonly and some other shareholders made an offer to Andy but were turned down. Not sure if Orel Hershiser was part of that group, but he is rumored to be a shareholder and fan of the products (would be a great influencer for BIEL). The Dr. Oz effect will be interesting, considering his appointment yesterday as Administrator of the Centers for Medicare and Medicaid Services. When Actipatch was featured on his show, it achieved record sales and depleted the inventory.
BIEL's prospects for achieving a 1,000% to 10,000% increase in pps are better than any other company on the market right now! The path to profitability will be accelerated by the tax-loss carryforward of about $40 million (no tax on first $40 million profit). If the company then declares that profits would be used for a share buyback program (after paying off the loans), the pps would soar ($1+) and the rise would be sustained.
ACTIPATCH WILL BE A "STANDARD OF CARE" PRODUCT!
With FDA clearance for treatment of knee, back, wrist, hips, ankles, plantar fasciitis and all musculoskeletal pain, how can it not, especially at the low price of $35 - with a much longer battery life than the competition! The bashers don't seem to understand that the Actipatch FDA clearance allows it to be sold over the counter (without a prescription). The RecoveryRX applications (post operative pain, edema, wound care, etc.) do require a doctor order. Add in RecoveryRx-Veterinary and you have over 10 billion potential repeat customers - every adult and pet on the planet (every month). Then there is the "wellness" market, as many people use Actipatch for Restless Leg Syndrome (RLS is estimated to affect 10% of adults worldwide), menstrual pain, migraines and other "off label" aches and pains.
RECOVERYRX-VETERINARY COULD/SHOULD BE A GOLDMINE!
The Assisi Loop sells over 300/month just on Amazon @ $329, with 1/20 the battery life. Assisi Loop customers are paying the equivalent of over $6,000 when you factor in the additional cost and lower battery life, but Assisi customers seem happy to pay it based on the 5-star reviews, such as the following from a customer in Japan 3-23-2025:
"When applied to the affected area, my dog relaxes a lot. This is the effect we were hoping for. I also tried it on my human back. This product is truly effective."
RecoveryRx-Veterinary should be sold as a two/pack - one for the vagus nerve and the other for the area of pain.
Right now, I doubt anything under $50 million would be considered (accounting for loans, etc.). That's out of my range, but in the future - after the pps increases, loans are paid off and a share buyback is implemented - I could see a point where a group of shareholders could get together and leverage their shareholdings to make an offer. Years ago, Simpsonly and some other shareholders made an offer to Andy but were turned down. Not sure if Orel Hershiser was part of that group, but he is rumored to be a shareholder and fan of the products (would be a great influencer for BIEL). The Dr. Oz effect will be interesting, considering his appointment yesterday as Administrator of the Centers for Medicare and Medicaid Services. When Actipatch was featured on his show, it achieved record sales and depleted the inventory.
BIEL's prospects for achieving a 1,000% to 10,000% increase in pps are better than any other company on the market right now! The path to profitability will be accelerated by the tax-loss carryforward of about $40 million (no tax on first $40 million profit). If the company then declares that profits would be used for a share buyback program (after paying off the loans), the pps would soar ($1+) and the rise would be sustained.
ACTIPATCH WILL BE A "STANDARD OF CARE" PRODUCT!
With FDA clearance for treatment of knee, back, wrist, hips, ankles, plantar fasciitis and all musculoskeletal pain, how can it not, especially at the low price of $35 - with a much longer battery life than the competition! The bashers don't seem to understand that the Actipatch FDA clearance allows it to be sold over the counter (without a prescription). The RecoveryRX applications (post operative pain, edema, wound care, etc.) do require a doctor order. Add in RecoveryRx-Veterinary and you have over 10 billion potential repeat customers - every adult and pet on the planet (every month). Then there is the "wellness" market, as many people use Actipatch for Restless Leg Syndrome (RLS is estimated to affect 10% of adults worldwide), menstrual pain, migraines and other "off label" aches and pains.
RECOVERYRX-VETERINARY COULD/SHOULD BE A GOLDMINE!
The Assisi Loop sells over 300/month just on Amazon @ $329, with 1/20 the battery life. Assisi Loop customers are paying the equivalent of over $6,000 when you factor in the additional cost and lower battery life, but Assisi customers seem happy to pay it based on the 5-star reviews, such as the following from a customer in Japan 3-23-2025:
"When applied to the affected area, my dog relaxes a lot. This is the effect we were hoping for. I also tried it on my human back. This product is truly effective."
RecoveryRx-Veterinary should be sold as a two/pack - one for the vagus nerve and the other for the area of pain.
(2)
(1)